$8M for NKT Therapeutics

Xconomy Boston — 

NKT Therapeutics, a Newton, MA-based startup built around technology from Boston’s Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital, announced it has raised $8 million in a Series A financing led jointly by SV Life Sciences and MedImmune Ventures. NKT, whose website says the financing closed in December 2008, is developing treatments for asthma, cancer, autoimmune diseases, and other ailments by targeting natural killer T cells, a type of white blood cell.

By posting a comment, you agree to our terms and conditions.

Comments are closed.